<DOC>
	<DOC>NCT00658879</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first Pegvisomant should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Patients need to be administered Pegvisomant in order to be enrolled in the surveillance. Patients not administered Pegvisomant.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>